P. Bakke (Bergen, Norway), E. Tzortzaki (Heraklion, Crete, Greece)
Plasma biomarker assay and the immuno-modulatory effect of erythromycin in COPD
J. R. Hurst, T. A. R. Seemungal, T. M. A. Wilkinson, W. R. Perera, R. J. Sapsford, J. A. Wedzicha (Royal Free Campus, United Kingdom)
|  |
Troponin T elevation and one year mortality after acute exacerbation of chronic obstructive pulmonary disease
A. Uysal, M. Sancak, A. Aynaci, G. Aras, F. Kadakal, V. Yilmaz (Istanbul, Turkey)
|   |
Transfer factor data are a good predictor of a reduction in airflow limitation among patients with COPD "stage 0"
T. Motegi, T. Ishii, N. Motohashi, H. Kurosaki, K. Yamada, A. Genma, K. Kida (Tokyo, Japan)
| |
The annual change in BOD and BODE in patients with chronic obstructive pulmonary disease
K. Ansari, A. Kay, J. Munby, I. Taylor, N. Keaney (Sunderland, United Kingdom)
| |
The natural history of COPD without co-morbidities: predictors of long-term mortality
J. M. Marin, M. Ciudad, R. Tejedor, S. J. Carrizo, B. R. Celli (Zaragoza, Spain; Boston, United States Of America)
| |
Chronic obstructive pulmonary disease in heart failure: prevalence, therapeutic and prognostic implications
P. Boschetto, A. Fucili, D. Beltrame, A. Potena, L. Ballerin, C. E. Mapp, L. M Fabbri, E. De Rosa, C. Ceconi, R. Ferrari (Ferrara, Modena, Italy)
| |
Left ventricular diastolic dysfunction in COPD without any risk factor may have association with myocardial ischemia
P. Bhattacharyya, D. Acharjee, S. Nag, S. Bardhan, M. Ghosh, R. Dey, S. Roy, N. De, R. K. Sharma, S. K. Sharma (Kolkata, India)
| |
Blood biomarkers in COPD: results from the ECLIPSE (evaluation of COPD longitudinally to identify predictive surrogate endpoints) cohort
B. Miller, L. Edwards, N. Locantore, D. Lomas, R. Tal-Singer (King of Prussia, Research Triangle Park, United States Of America; Cambridge, United Kingdom)
| |